Skip to main content

Table 4 Prognostic factors of overall survival: univariate and multivariate analysis

From: From IB2 to IIIB locally advanced cervical cancers: report of a ten-year experience

Variables Tested vs adverse criteria Adverse criterion present median overall survival (months) Adverse criterion absent median overall survival (months) p-value (Log rank test) Adjusted Hazard Ratio 95% CI p-value (Cox model)
Age (years) ≥ 65 (vs < 65) 73.1 90.9 p = 0.361
PS PS > 1 (vs ≤ 1) 48.6 > 124.0* p < 0.001 2.86 1.41–5.79 p = 0.003
Histology No SCC (vs SCC) 61.2 124.9 p = 0.262
Differentiation Moderate or low (vs high) 73.1 90.9 p = 0.899
FIGO stage III (vs IB2 and II) 37.4 90.9 p = 0.336
Pelvic lymph nodes involvement Yes (vs no) 41.1 > 73.1* p = 0.003 1.95 1.03–3.69 p = 0.040
MRI tumor size (mm) ≥ 50 (vs < 50) 32 > 124.9* p = 0.006
Hemoglobin (g/dL) < 11 (vs ≥ 11) 13.0 > 63.0* p = 0.013
Radiotherapy 3D–CRT (vs IMRT or VMAT) 73 > 61.0* p = 0.500    
Concurrent chemotherapy No (vs yes) 17 125.0 p = 0.014 2.33 1.06–5.16 p = 0.035
Brachytherapy No (vs yes) 37.4 124.9 p = 0.428
OTT (days) > 55 (vs ≤ 55) 62.9 124.9 p = 0.428
Complete tumor sterilization No (vs yes) 90.9 > 69.1* p = 0.256
  1. Abbreviations: CI Confident Interval, SCC Squamous Cell Carcinoma, PS Performance Status FIGO International Federation of Gynecology and Obstetrics, MRI Magnetic Resonance Imaging; 3DCRT 3D Conformal Radiotherapy, IMRT Intensity Modulated Radiotherapy, VMAT Volumetric Modulated Arc Therapy, OTT Overall Treatment Time
  2. Legend: Univariate analysis was performed using Log-rank test, multivariate analysis using Cox model
  3.  * = 95% CI lower bound (not enough event to reach median overall survival)